Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription

Abstract Background and Aims Inflammageing represents both a critical pathophysiological hallmark and independent risk factor for myocardial infarction (MI), with age‐related increases observed in MI incidence and severity of post‐MI ventricular remodelling. Novel therapeutic strategies targeting in...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Gu, Yingqiang Du, Jin'ge Zhang, Jiyu Li, Haiyun Chen, Yujie Lin, Yue Wang, Chunli Zhang, Shiyu Lin, Nannan Hao, Chengyi Peng, Jiacheng Ge, Jin Liu, Yan Liang, Yongjie Zhang, Xiaoyan Wang, Fang Wang, Jianliang Jin
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Clinical and Translational Medicine
Subjects:
Online Access:https://doi.org/10.1002/ctm2.70344
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849434902858039296
author Xin Gu
Yingqiang Du
Jin'ge Zhang
Jiyu Li
Haiyun Chen
Yujie Lin
Yue Wang
Chunli Zhang
Shiyu Lin
Nannan Hao
Chengyi Peng
Jiacheng Ge
Jin Liu
Yan Liang
Yongjie Zhang
Xiaoyan Wang
Fang Wang
Jianliang Jin
author_facet Xin Gu
Yingqiang Du
Jin'ge Zhang
Jiyu Li
Haiyun Chen
Yujie Lin
Yue Wang
Chunli Zhang
Shiyu Lin
Nannan Hao
Chengyi Peng
Jiacheng Ge
Jin Liu
Yan Liang
Yongjie Zhang
Xiaoyan Wang
Fang Wang
Jianliang Jin
author_sort Xin Gu
collection DOAJ
description Abstract Background and Aims Inflammageing represents both a critical pathophysiological hallmark and independent risk factor for myocardial infarction (MI), with age‐related increases observed in MI incidence and severity of post‐MI ventricular remodelling. Novel therapeutic strategies targeting inflammageing‐driven mechanisms are urgently required to attenuate adverse ventricular remodelling following MI. This investigation was designed to elucidate the impact of fibroblast‐specific p16INK4a on inflammageing‐associated ventricular remodelling after MI and to develop a targeted nanotherapy to mitigate this process. Methods and Results We found that p16‐mediated inflammageing positively correlated with the severity of post‐infarction ventricular remodelling in patients. POSTN‐driven p16INK4a knockout improved cardiac function, and reduced ventricular remodelling, myocardial inflammation and NLRP3 signalling activation following MI through downregulating STAT3‐mediated NLRP3 inflammasome and upregulating glutathione metabolism pathway in fibroblasts. P16INK4a overexpression induced NLRP3 signalling activation through upregulating NLRP3 transcribed by STAT3 in fibroblasts. In terms of mechanisms, p16INK4a interacted with STAT3, which depended on the SH2 domain of STAT3; P16INK4a promoted the interaction of EZH2 and STAT3, increased the di‐methylation on K49 and phosphorylation on Y705 of STAT3 by EZH2, and promoted NLRP3 transcription through regulating histone modification in the NLRP3 promoter by interfering the formation of Bmi‐1‐EZH2 or Bmi‐1‐BCL6 complex in fibroblasts. Injection of p16INK4a‐accumulated ageing cardiac fibroblasts, or p16INK4a overexpression adenovirus aggravated profibrosis and proinflammation in MI area. However, a novel FH peptide ‘FHKHKSPALSPV’‐neutrophil membrane proteins (NMPs)‐artificial lipid (Li) membranes‐mesoporous silica nanoparticle (MSN) core (FNLM)‐nanocaged p16INK4a‐siRNA, as a newly constructed nanomaterial drug, could prevent post‐infarction ventricular remodelling through inhibiting NLRP3 transcription in targeted cardiac fibroblasts and ameliorating proinflammation and profibrosis. Conclusions P16INK4a drives inflammageing‐mediated post‐MI ventricular remodeling by activating STAT3/NLRP3 signaling in fibroblasts. Targeting p16INK4a via FNLM‐siRNA nanotherapy represents a novel strategy to ameliorate adverse cardiac remodelling, offering translational potential for clinical intervention. Key points Mechanistic Insight: P16INK4a activates NLRP3 transcription via STAT3‐EZH2 crosstalk, disrupting epigenetic complexes (Bmi‐1‐EZH2/BCL6) to exacerbate post‐MI remodelling. Therapeutic Innovation: A fibroblast‐targeted FNLM nanoparticle delivering p16INK4a‐siRNA effectively silences NLRP3, reducing post‐MI inflammageing. Translational Impact: This study identifies p16INK4a‐STAT3 as a druggable axis and proposes FNLM‐p16INK4a‐siRNA as a promising nanotherapy for clinical post‐MI care.
format Article
id doaj-art-dbe52b750eae45a3855eeca1b10e6260
institution Kabale University
issn 2001-1326
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series Clinical and Translational Medicine
spelling doaj-art-dbe52b750eae45a3855eeca1b10e62602025-08-20T03:26:29ZengWileyClinical and Translational Medicine2001-13262025-06-01156n/an/a10.1002/ctm2.70344Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcriptionXin Gu0Yingqiang Du1Jin'ge Zhang2Jiyu Li3Haiyun Chen4Yujie Lin5Yue Wang6Chunli Zhang7Shiyu Lin8Nannan Hao9Chengyi Peng10Jiacheng Ge11Jin Liu12Yan Liang13Yongjie Zhang14Xiaoyan Wang15Fang Wang16Jianliang Jin17Department of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaDepartment of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaThe Research Center for AgingAffiliated Friendship Plastic Surgery Hospital of Nanjing Medical UniversityNanjingChinaDepartment of RheumatologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of GeriatricsThe Second Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of Oral and Maxillofacial SurgeryAffiliated Stomatological Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaDepartment of CardiologyThe Affiliated Hospital of Jiangnan UniversityWuxiJiangsuChinaDepartment of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChinaDepartment of Human Anatomy, School of Basic Medical Sciences, Key Laboratory for Aging & Disease, School of Biomedical Engineering and InformaticsNanjing Medical UniversityNanjingJiangsuChinaAbstract Background and Aims Inflammageing represents both a critical pathophysiological hallmark and independent risk factor for myocardial infarction (MI), with age‐related increases observed in MI incidence and severity of post‐MI ventricular remodelling. Novel therapeutic strategies targeting inflammageing‐driven mechanisms are urgently required to attenuate adverse ventricular remodelling following MI. This investigation was designed to elucidate the impact of fibroblast‐specific p16INK4a on inflammageing‐associated ventricular remodelling after MI and to develop a targeted nanotherapy to mitigate this process. Methods and Results We found that p16‐mediated inflammageing positively correlated with the severity of post‐infarction ventricular remodelling in patients. POSTN‐driven p16INK4a knockout improved cardiac function, and reduced ventricular remodelling, myocardial inflammation and NLRP3 signalling activation following MI through downregulating STAT3‐mediated NLRP3 inflammasome and upregulating glutathione metabolism pathway in fibroblasts. P16INK4a overexpression induced NLRP3 signalling activation through upregulating NLRP3 transcribed by STAT3 in fibroblasts. In terms of mechanisms, p16INK4a interacted with STAT3, which depended on the SH2 domain of STAT3; P16INK4a promoted the interaction of EZH2 and STAT3, increased the di‐methylation on K49 and phosphorylation on Y705 of STAT3 by EZH2, and promoted NLRP3 transcription through regulating histone modification in the NLRP3 promoter by interfering the formation of Bmi‐1‐EZH2 or Bmi‐1‐BCL6 complex in fibroblasts. Injection of p16INK4a‐accumulated ageing cardiac fibroblasts, or p16INK4a overexpression adenovirus aggravated profibrosis and proinflammation in MI area. However, a novel FH peptide ‘FHKHKSPALSPV’‐neutrophil membrane proteins (NMPs)‐artificial lipid (Li) membranes‐mesoporous silica nanoparticle (MSN) core (FNLM)‐nanocaged p16INK4a‐siRNA, as a newly constructed nanomaterial drug, could prevent post‐infarction ventricular remodelling through inhibiting NLRP3 transcription in targeted cardiac fibroblasts and ameliorating proinflammation and profibrosis. Conclusions P16INK4a drives inflammageing‐mediated post‐MI ventricular remodeling by activating STAT3/NLRP3 signaling in fibroblasts. Targeting p16INK4a via FNLM‐siRNA nanotherapy represents a novel strategy to ameliorate adverse cardiac remodelling, offering translational potential for clinical intervention. Key points Mechanistic Insight: P16INK4a activates NLRP3 transcription via STAT3‐EZH2 crosstalk, disrupting epigenetic complexes (Bmi‐1‐EZH2/BCL6) to exacerbate post‐MI remodelling. Therapeutic Innovation: A fibroblast‐targeted FNLM nanoparticle delivering p16INK4a‐siRNA effectively silences NLRP3, reducing post‐MI inflammageing. Translational Impact: This study identifies p16INK4a‐STAT3 as a druggable axis and proposes FNLM‐p16INK4a‐siRNA as a promising nanotherapy for clinical post‐MI care.https://doi.org/10.1002/ctm2.70344nanotherapyNLRP3 inflammasomep16INK4apost‐infarction ventricular remodellingSTAT3
spellingShingle Xin Gu
Yingqiang Du
Jin'ge Zhang
Jiyu Li
Haiyun Chen
Yujie Lin
Yue Wang
Chunli Zhang
Shiyu Lin
Nannan Hao
Chengyi Peng
Jiacheng Ge
Jin Liu
Yan Liang
Yongjie Zhang
Xiaoyan Wang
Fang Wang
Jianliang Jin
Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription
Clinical and Translational Medicine
nanotherapy
NLRP3 inflammasome
p16INK4a
post‐infarction ventricular remodelling
STAT3
title Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription
title_full Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription
title_fullStr Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription
title_full_unstemmed Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription
title_short Fibroblasts‐specific p16INK4a exacerbates inflammageing‐mediated post‐infarction ventricular remodelling through interacting with STAT3 to regulate NLRP3 transcription
title_sort fibroblasts specific p16ink4a exacerbates inflammageing mediated post infarction ventricular remodelling through interacting with stat3 to regulate nlrp3 transcription
topic nanotherapy
NLRP3 inflammasome
p16INK4a
post‐infarction ventricular remodelling
STAT3
url https://doi.org/10.1002/ctm2.70344
work_keys_str_mv AT xingu fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT yingqiangdu fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT jingezhang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT jiyuli fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT haiyunchen fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT yujielin fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT yuewang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT chunlizhang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT shiyulin fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT nannanhao fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT chengyipeng fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT jiachengge fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT jinliu fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT yanliang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT yongjiezhang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT xiaoyanwang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT fangwang fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription
AT jianliangjin fibroblastsspecificp16ink4aexacerbatesinflammageingmediatedpostinfarctionventricularremodellingthroughinteractingwithstat3toregulatenlrp3transcription